RecruitingNCT06171659

FDG PET/MR Imaging of Peripheral Pain Generators

FDG PET/MR Imaging of Peripheral Pain Generators in Persistent Post-Surgical Pain (PPSP)

Sponsor

University of Wisconsin, Madison

Enrollment

128 participants

Start Date

Nov 19, 2024

Study Type

OBSERVATIONAL

Conditions

Pain Nociceptive Pain

Summary

The purpose of this research is to determine if a PET/MRI scan using FDG can accurately identify the source of chronic pain. Identifying the source of pain may help doctors treat chronic pain more effectively. Approximately 128 participants will be enrolled and can expect to be on study for up to 12 months.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called FDG radiotracer, a medical device called PET/CT imaging, and others for people with nociceptive pain and pain. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFDG radiotracer

Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

DEVICEPET/MRI

positron emission tomography and magnetic resonance imaging

DEVICEPET/CT imaging

positron emission tomography and computed tomography imaging